Relmada Therapeutics closed at $4.17 on Nov 4, down 2.34%, 46.9% below its 52-week closing high. Volume of 2.6M shares was 1.55× its 20-day average (above normal).
Split-adjusted performance: +27.1% over one month, -46.9% over six months, +89.5% over one year.
Short interest was 12.2M shares at the Oct 15 settlement, down 9.3% from the prior report (14.0% of float, 8.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| RLMDRelmada Therapeutics | $4.17 | −2.34% | −46.9% | — | — | — | $444.8M | |
| CRMDCorMedix | $5.66 | +1.80% | −29.7% | +156.5% | 25.5% | 2.4 | $441.2M | Compare |
| INDPIndaptus Therapeutics | $3.30 | +1.85% | +61.0% | — | — | — | $439.7M | Compare |
| TLRYTilray Brands | $2.96 | +11.70% | −48.6% | +22.7% | −16.8% | — | $437.5M | Compare |
| PRTAProthena | $8.39 | +2.19% | −25.0% | −77.1% | −1839.9% | — | $430.7M | Compare |
| PHATPhathom Pharmaceuticals | $5.68 | −1.05% | −55.2% | +71.1% | −16.4% | — | $461.7M | Compare |
| GYREGyre Therapeutics | $4.44 | 0.00% | −44.8% | −2.1% | −40.1% | — | $470.8M | Compare |
| AQSTAquestive Therapeutics | $3.80 | −2.06% | −10.2% | +38.1% | −165.5% | — | $476.9M | Compare |
| ALTAltimmune | $2.12 | +3.92% | −35.0% | −100.0% | — | — | $412.4M | Compare |
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
